CSF t-tau, p-tau, and total α-Syn levels may increase with disease stage, and high levels of these factors have been associated with cognitive impairment in patients with more advanced disease, but not those at an early disease stage (Hall et al., 2016). The gene discussed is MAPT; the disease is Cognitive impairment.